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Unsatisfactory results of traditional methods of cancer 
therapy determine the need for search of new means ele­
vating anticancer resistance of organism. Activation of the 
mechanisms of immune surveillance is an important way 
to solve the task. Presently the development of immuno­
therapeutical approaches, in particular, cancer vaccines 
(CV) is considered as the most promising approach. 
Analysis of modern data evidence on high prophylactic 
and therapeutic efficacy of combined use of specific CV 
with adjuvants of different origin [1, 2], including various 
cytokines able to stimulate immune response [3, 4]. 
Interferon (IFN) was among the first cytokines success­
fully applied in clinical practice for activation of unspecific 
resistance upon viral infections and immunodeficiency 
state [5]. IFN as natural factor of antitumor defense is one 
of key modulators of immune response, and influences 
the processes of antigen recognition, differentiation, 
recruitment and functional activity of immunocompetent 
cells. Also IFN has direct influence on tumor growth and 
differentiation and act as apoptosis inducer [6, 7]. 
Effects of IFN related to elevation of tumor immu­
nogenecity and its altered sensitivity to cytotoxic and 
differentiation­stimulating action of T­lymphocytes are 
of particular interest [7], as well as the role of IFN at 
combination with other biological agents. The special 
attention is focused on the study of effects of IFN com­
bined with active specific immunization [8–10]. 
That’s why the search for compounds able to activate 
synthesis of endogeneous IFN — so called IFN inducers, 
is of great importance [11, 12]. Amixin (tyrolon, 2,7­bis 
[2­(diethyamino) etoxy] fluorenon­9 dihydrochloride) is 
a peroral low molecular weight inducer of endogenous 
IFN that may be used for prophylaxis and therapy of 
a number of diseases. Activity of this preparation is related 
to its immunomodulating properties, ability to normalize 
impaired immune reaction of organism, renew a balance of 
important elements of immune system [13–15]. The data 
on significant antitumor activity of amixin were obtained in 
experimental studies using model tumors, and in clinical 
trials for melanoma, breast cancer, renal­cell cancer [13]. 
Moreover, it has been shown that combined use of amixin 
and anticancer drugs promoted growth inhibition of ex­
perimental tumors and decreased metastasis rate [16].
In our earlier studies it has been shown that intro­
duction of IFN to CV significantly elevated efficacy of 
vaccine therapy of Lewis lung carcinoma [17]. The aim 
of present research was to evaluate possible benefits 
of the use of amixin for elevation of CV efficacy, and to 
compare the obtained results with these for IFN.
MATERIALS AND METHODS
In the work, female Balb/c mice weighting 18–20 g, 
2.0–2.5 months old bred in the vivarium of IEPOR 
NASU (Kyiv, Ukraine) were used. As tumor model, solid 
form of sarcoma­37 was used.
Experimental animals (n = 8 per group) were routinely 
transplanted intramuscularly with 5.0 х 105 tumor cells, 
and received the treatment according to the scheme 
of experiment (Table 1). CV was prepared from sar­
coma­37 cells and cytotoxic lectine (CL) from B. subtilis 
B-7025 according to the method [18, 19]. CV was admini­
stered 5 times at equal doses (0.3 ml) subcutaneously 
on days 1, 4, 8, 12 and 15 after tumor transplantation. 
ELEVATION OF EFFICACY OF CANCER VACCINE COMbINED 
wITH INTERFERON AND INDUCER OF ENDOGENEOUS 
INTERFERON SYNTHESIS AMIXIN
G.P. Potebnya1, *, G.S. Lisovenko1, N.V. Trokhimenko1, N.L. Cheremshenko1,  
G.V. Didenko1, A.S. Reder2, S.A. Andronati2 
1R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology NAS of Ukraine, Kyiv 03022, 
Ukraine 
2O.V. Bogatsky Physico-Chemical Institute NAS of Ukraine, Odesa 65011, Ukraine
Aim: To study in vivo efficacy of combined administration of cancer vaccine (CV), interferon (IFN) and inducer of endogenous IFN — amixin. 
Materials and Methods: Sarcoma-37 cells were transplanted to female Balb/c mice. For the treatment, CV prepared from sarcoma-37 cells 
with the use of cytotoxic lectines from B. subtilis B-7025, murine IFN and amixin or their combinations were used. IFN production, 
content of circulating immune complexes and level of specific IgG antibodies in blood serum were determined by standard immunologic 
methods. Results: Using solid form of sarcoma-37 it has been shown that introduction of IFN and amixin significantly elevated efficacy 
of vaccine therapy, in particular index of tumor growth inhibition reach 89.2% and 81.7%. Upon combined use of CV and IFN or CV and 
amixin (25 mg/kg) respectively. Significant prolongation of average life span of the animals treated with CV and IFN or CV and amixin 
(25 mg/kg) has been registered (up to 92.7 ± 10.4 and 95.0 ± 6.2 days respectively, vs 46.8 ± 1.5 days for control animals). Conclusion: 
Obtained results have shown expediency of the development of schemes for combined introduction of CV with exogenous IFN, and with 
inducer of endogenous IFN (amixin) for elevation of efficacy of vaccine therapy.
Key Words: cancer vaccine, interferon, amixin, experimental tumor, immunologic index.
Received: March 5, 2008. 
*Correspondence: Fax: +38 (044) 258-16-56 
 E-mail: iris@onconet.kiev.ua 
Abbreviations used: ALS — average life span; CIC — circulating 
immune complex; CV — cancer vaccine; IFN — interferon; TGI — 
tumor growth inhibition.
Exp Oncol 2008
30, 4, 319–323
320 Experimental Oncology 30, 319–323, 2008 (December)
Experimental protocols and procedures were aproved 
by the Ethical Committee of IEPOR. 
Table 1. Therapeutic experiment scheme for a study of efficacy of 
combined use of CV and IFN or CV and amixin in sarcoma-37-bearing mice 
Group Treatment Scheme of administrationCV IFN or amixin
1 CV By 0.3 ml; s/c; 5-times; 
at days 1, 4, 8, 12 and 15 
—
2 IFN — By 1000 U., 5-times; i/p; 
at days 1,3,7, 11 and 14 
3 CV + IFN By 0.3 ml; s/c; 5-times; 
at days 1, 4, 8, 12 and 15 
By 1000 U, 5- times; i/p; 
at days 1,3,7, 11 and 14 
4 Amixin 
(10 mg/kg)
— By 10 mg/kg in 0.5 ml PS; 
per os, 2 h prior to CV
5 CV + amixin 
(10 mg/kg)
By 0.3 ml, s/c; 5-times; 
at days 1, 4, 8, 12 and 15 
By 10 mg/kg in 0.5 ml PS; 
per os, 2 h prior to CV
6 Amixin 
(25 mg/kg)
— By 10 mg/kg in 0.5 ml PS; 
per os, 2 h prior to CV
7 CV + amixin 
(25 mg/kg)
By 0.3 ml, s/c; 5-times; 
at days 1, 4, 8, 12 and 15 
By 25 mg/kg in 0.5 ml PS; 
per os, 2 h prior to CV
8 Control of 
trans plantation
— —
Preparation of murine IFN kindly gifted by Dr. Kudrya­
vets was administered 5 times intraperitoneally by 
1000 U in 0.5 ml physiologic solution (PS) 24 h prior to 
CV introduction. Substance of amixin was supplied by 
OSS “Interkhim”, preparation was administered p.o. 
5 times at the doses of 0 mg/kg or 25 mg/kg in 0.5 ml, 
2 h prior to CV administration. The animals from control 
group received PS in equal manner and time points. 
Efficacy of treatment was evaluated by common 
tumor growth characteristics, survival and average life 
span (ALS) of control and experimental animals. 
Immunological studies were performed at days 14, 
30 and 40 after tumor transplantation, and include deter­
mination of the content of circulating immune complexes 
(CIC) isolated by precipitation with PEG­6000, and analysis 
of the level of specific IgG antibodies in blood serum by 
immunoenzyme reaction [20]. Production of IFN was 
evaluated by titration of blood serum for its ability to inhibit 
cytopathogenic action of vesicular stomatitis virus [21].
Significance of the differences between the para­
meters was evaluated by Student’s t­criterium [22]. Cal­
culations were done using Microsoft Excel program.
RESULTS AND DISCUSSION
Analysis of growth dynamics of sarcoma­37 in the 
groups of animals treated with studied preparation has 
demonstrated its significant inhibition (Fig. 1). For exam­
ple, in animals that received IFN or amixin at monoregi­
men, tumor growth inhibition (TGI) index was in a range 
65–75%, but the difference between experimental 
groups was insignificant (p > 0.05) (Fig.1, a). Respective 
index in mice treated with CV was 81.2% (Fig. 1, b). 
Upon application of combined scheme of introduction 
of studied preparations, the best results were observed in 
mice that received CV and IFN: TGI was equal to 89.2%. 
Combined introduction of CV with amixin was also effec­
tive, if amixin was introduced at the dose of 25 mg/kg: 
TGI was 81.7%. The results of combined use of CV with 
10 mg/kg amixin were more worse then in the case of sep­
arate administration of CV or amixin (TGI = 53.8%, 81.2% 
and 66.5%, respectively; p < 0.05). It seems that low­dose 
amixin caused even antagonistic effect in its combination 
with CV. The mechanisms of such effect should be clarified.
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Fig. 1. Dynamics of tumor growth in sarcoma­37­bearing mice treated 
with IFN or amixin at monoregimen (a) or in combination with CV (b)
The studied preparations possess different effect 
on efficacy of sarcoma­37 transplantation (Fig. 2, a). 
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Fig. 2. Efficacy of sarcoma­37 cells transplantation into animals treated 
with IFN or amixin at monoregimen (a) or in combination with CV (b)
At day 12, all animals from control group develop 
tumors, but introduction of IFN or amixin at the doses 
of 25 and 10 mg/kg caused retardation of this process 
(at the day 12 indexes of transplantation were 57.1; 
50.0 and 37.5%, respectively), however later the tumors 
developed in all animals. In particular, in mice treated 
with amixin at both doses, the tumors developed at the 
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day 41. Introduction of CV resulted in decreased transp­
lantation efficacy in all experimental groups (Fig. 2, b). 
In CV­treated mice this index decreased to 62.5%, and 
in animals treated with combination of CV with IFN or 
amixin transplantation efficacy was 75%. 
Animal survival rate (Fig. 3) was elevated in all experi­
mental groups: while in control group all animals die be­
fore day 54, in IFN­treated mice this index was 71 days, 
and only 62.5% animals died at day 84, if both doses 
of amixin were used. The highest survival has been 
recorded in mice treated with combination of CV with 
IFN or amixin (25 mg/kg) — at day 84, only 25% animals 
dies in each group, and such index was significantly 
higher compared to the use of CV at monoregimen or 
with amixin at low dose (62.5% in each case).
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Fig. 3. Survival of sarcoma­37­bearing animals treated with IFN 
or amixin at monoregimen (a) or in combination with CV (b)
Analysis of ALS (Table 2) was in agreement with these 
observations: the best results were registered exactly upon 
combined use of CV and IFN or CV with 25mg/kg amixin 
(ALS indexes were 92.7 ± 10.4 and 95.0 ± 6.2 days vs 
46.8 ± 1.5 days in control group, p < 0.05). These indexes 
were significantly higher than these for separate use of 
each preparation (ALS indexes in mice treated with CV, 
IFN or 25 mg/kg amixin at monoregimen were 79.3 ± 10.9, 
64.7 ± 10.1, and 79.0 ± 5.9 days, respectively). So, above­
mentioned data allow state elevation of efficacy of CV upon 
its combined use with IFN or amixin. Decreased amixin 
dose (10 mg/kg) introduced into combined scheme did 
not cause such effect: ALS did not differ significantly 
from that for separate introduction of (77.0 ± 7.8 vs 
77.0 ± 10.1 days, р > 0.05), but was significantly higher 
than ALS in control group (р < 0.05).
Determination of IFN titers in blood serum of 
experimental animals did not reveal the peculiari­
ties explaining clearly the different efficacy of used 
schemes of IFN or amixin administration (Table 3). 
Compared to the control group, in all experimental 
groups there was observed elevation of IFN titers at 
day 14 and especially at day 30 of tumor growth, and its 
decrease at day 40. In control tumor bearing animals 
these indexes were 1 : 64; 1 : 64; 1 : 16 respectively. 
Table 2. Average life span of sarcoma-37-bearing mice treated with 
IFN or amixin at monoregimen or in combination with CV 
Group Treatment Number of animals
ALS
Х ± m t MI%
1 CV 8 79.3 ± 10.9 2.93 69.4
2 IFN 8 64.7 ± 10.1 1.73 38.2
3 CV + IFN 8 92.7 ± 10.4 4.31 98.0
4 CV + amixin 10 mg/kg 8 77.0 ± 7.8 3.79 64.5
5 Amixin 10 mg/kg 8 77.0 ± 10.1 3.04 66.8
6 CV + amixin 25 mg/kg 8 95.0 ± 6.2 7.56 102.9
7 Amixin 25 mg/kg 8 79.0 ± 5.9 5.32 68.8
8 Control 8 46.8 ± 1.5
Table 3. IFN titers in blood serum of sarcoma-37-bearing mice treated 
with IFN or amixin at monoregimen or in combination with CV
Group Treatment Days after tumor transplantation 14 30 40
1 CV 1 : 128 1 : 128 1 : 16
2 IFN 1 : 32 1 : 16 1 : 16
3 CV + IFN 1 : 32 1 : 64 1 : 64
4 CV + amixin 10 mg/kg 1 : 64 1 : 128 1 : 32
5 Amixin 10 mg/kg 1 : 64 1 : 256 1 : 32
6 CV + amixin 25 mg/kg 1 : 64 1 : 256 1 : 32
7 Amixin 25 mg/kg 1 : 64 1 : 128 1 : 16
8 Control 1 : 64 1 : 64 1 : 16
9 Intact animals 1 : 16 1 : 16 1 : 16
Using immunoenzyme assay (IEA) we have deter­
mined the level of sarcoma­37 antigens in blood serum 
of experimental animals (Fig. 4). The results evidence 
on significant increase of this index in control animals 
during all terms of observation, even at late stages of 
tumor growth, however, in mice treated with IFN or CV at 
monoregimen or in combination, the level of antitumor 
antibodies was higher, pointing on immunostimulating 
action of the preparations. The use of amixin at the dose 
of 25 mg/ml in both schemes significantly decreased this 
index compared to the control. In contrary, introduction 
of low­dose amixin resulted in the level of antibodies at 
days 30–40 of tumor growth close to control values, while 
its combined use with CV also leads to sharp decrease of 
IgG levels at the late terms of tumor development.
The study of content of medium­molecular weight 
CIC in blood of control tumor­bearing group has shown 
its elevation compared to intact animals, as well as its 
drastic increase (up to 0.777 ou.) at late stages of tumor 
growth (Fig. 5). Upon administration of IFN, the dynam­
ics of CIC content seems to be similar to that of intact 
animals, except its low value (0.183 ou.) at day 14 of 
tumor growth. At day 14 similarly low level of CIC has 
been detected also in the case of CV administration 
(at monoregimen or in combination with IFN), but in 
this case at day 40, sharp decrease of CIC level was 
observed after elevation of this index at day 30 charac­
teristic for the majority of experimental groups. 
In contrary, introduction of amixin was accompanied 
with elevation of CIC level at day 14 of tumor growth 
(0.520–0.540 ou), close to this index in the group of 
tumor­bearing control animals. However, at day 40, CIC 
level has been decreasing fluently (25 mg/ml dose), or 
sharply (10 mg/ml dose). Combined use of amixin and CV 
also leads to sharp decrease of CIC content in blood serum 
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at respective time point. It is necessary to note that at late 
terms after tumor transplantation (day 40) in mice treated 
with CV or amixin by different schemes, sharp decrease 
of this index has been registered compared to control ani­
mals; according to the data of literature, such effect point 
on favorable prognosis of the disease [23, 24]. In our study 
it was accompanied by significant tumor growth inhibition 
and elevation of life span of vaccinated animals. 
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Fig. 4. IgG levels in blood serum of sarcoma­37­bearing mice treated 
with IFN or amixin at monoregimen (a) or in combination with CV (b)
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Fig. 5. CIC levels in sarcoma­37­bearing mice treated with IFN 
or amixin at monoregimen (a) or in combination with CV (b)
In conclusion, above mentioned results have de­
monstrated that inducer of synthesis of endogenous 
IFN amixin at a dose of 25 mg/kg as well as exogenous 
IFN at a dose of 1000 U are able to elevate equally an­
ticancer action of the vaccine. Our data evidence on 
possibility for improvement of efficacy of cancer vaccine 
via development of combined schemes for its use. 
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ПОВЫШЕНИЕ ЭФФЕКТИВНОСТИ ПРОТИВООПУХОЛЕВОЙ 
ВАКЦИНЫ ИНТЕФЕРОНОМ И ИНДУКТОРОМ СИНТЕЗА 
ЭНДОГЕННОГО ИНТЕРФЕРОНА — АМИКСИНОМ
Цель: изучить в эксперименте эффективность комбинированной схемы введения противоопухолевой вакцины (CV) с интер-
фероном (ИФН) и индуктором эндогенного ИФН — амиксином. Материалы и методы: саркому-37 трансплантировали 
мышам-самкам Balb/c. Для лечения использовали CV, приготовленную из клеток саркомы-37 с помощью цитотоксиче-
ских лектинов B. subtilis B-7025, мышиный ИФН (1000 ед.) и амиксин (10 и 25 мг/кг). Иммунологические исследования 
включали определение в сыворотке крови титров ИФН, количества циркулирующих иммунных комплексов и уровня 
специфических противоопухолевых IgG-антител. Результаты: на модели солидной формы саркомы-37 показано, что 
применение ИФН и амиксина достоверно способствует повышению результатов вакцинотерапии, а именно, при комби-
нированном использовании CV и ИФН индекс торможения опухолевого роста (ИТО) достигал 89,2%; при сочетании CV 
и амиксина (25 мг/кг) ИТО составил 81,7%. Зарегистрировано существенное увеличение средней продолжительности 
жизни животных, получивших CV с ИФН или амиксином (25 мг/кг), до 92,7 ± 10,4 и 95,0 ± 6,2 сут соответственно, по 
сравнению с такой контрольных мышей (46,8 ± 1,5 сут, p < 0,05). Выводы: полученные результаты свидетельствуют о 
перспективности разработки комбинированных схем введения CV как с препаратом экзогенного ИФН, так и с индуктором 
эндогенного ИФН (амиксин), что позволяет повысить эффективность вакцинотерапии.
Ключевые слова: противоопухолевая вакцина, интерферон, амиксин, экспериментальная опухоль, показатели иммунитета. 
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